Reference entry · Thymic immunomodulatory peptide
Thymosin Alpha-1
Also known as: Tα1 · Thymalfasin · thymosin α1
- Class
- Thymic immunomodulatory peptide
- Size
- 28 amino acids
- Primary targets (literature)
- Toll-like receptors; dendritic and T-cell modulation
- Regulatory context
- Approved in some countries (e.g., thymalfasin) but not universally FDA-approved. RUO catalog batches require independent COA verification.
Overview
Thymosin alpha-1 is a 28-amino-acid thymic peptide with decades of immunology research and formal clinical programs in some jurisdictions. Catalog material is not interchangeable with approved drug presentations without verified identity.
Mechanism in research literature
Literature describes enhancement of T-cell and dendritic-cell function, TLR-mediated signaling, and cytokine modulation in immune-deficiency and viral-hepatitis research contexts.
Common research focus areas
- Immunomodulation in viral and immune-deficiency trials
- Dendritic-cell and T-cell assay literature
- Approved vs. catalog material distinction
- 28-mer sequence and acetylation state verification
Full literature roundup
Read the cited research summary
A 28-amino-acid thymic peptide with decades of immunology research and formal clinical programs in some jurisdictions. What the literature reports within an RUO frame.
Thymosin Alpha-1 research roundup · 7 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.